Department of Anatomy, Keimyung University School of Medcine, Daegu 42601, Korea.
Department of Radiation Oncology, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu 42601, Korea.
Medicina (Kaunas). 2022 Jan 20;58(2):155. doi: 10.3390/medicina58020155.
EZH2 is overexpressed in hepatocellular carcinoma (HCC) and is correlated with poor prognosis. However, its clinical significance and molecular mechanism have not been studied in HCC. In this study, clinical and prognostic values of EZH2 was studied using Total Cancer Genome Atlas (TCGA) data and then, these data were confirmed in Huh1 and HepG2 cell lines. : We used the TCGA database from cBioPortal. In addition, we analyzed EZH2 mRNA levels in HCC cell lines and its correlation with STAT3 and EZH2. According to TCGA, EZH2 had a prognostic value in various cancers, especially in HCC. Furthermore, EZH2 in HCC was correlated with N stage ( = 0.045) and alpha-fetoprotein (AFP) > 20 ng/mL ( < 0.01). However, a negative association between EZH2 and age ( = 0.027) was found. The overall survival result of HCC was significantly poorer in patients with high EZH2 expression. In addition, the recurrence rate was also significantly higher in patients with high expression of EZH2 than those with low expression (χ2 = 16.10, < 0.001). EZH2 expression was negatively correlated with STAT3 expression among EZH2-associated genes (R = -0.163, = 0.002). EZH2 expression level was down-regulated to 50% or less compared to the control group treated negative siRNA. MTT assays showed that EZH2-siRNA affected on the viability of HCC cell line significantly. In conclusion, the overexpression of EZH2 was an independent biomarker for poor outcomes of HCC. However, more in vivo studies are required to identify the downstream target genes in HCC to improve our understanding of the biological role of EZH2 in HCC.
EZH2 在肝细胞癌 (HCC) 中过表达，与预后不良相关。然而，其在 HCC 中的临床意义和分子机制尚未得到研究。本研究使用 TCGA 数据研究 EZH2 的临床和预后价值，然后在 Huh1 和 HepG2 细胞系中验证这些数据。我们使用了 cBioPortal 中的 TCGA 数据库。此外，我们分析了 HCC 细胞系中 EZH2 mRNA 水平及其与 STAT3 和 EZH2 的相关性。根据 TCGA，EZH2 在各种癌症中具有预后价值，特别是在 HCC 中。此外，EZH2 在 HCC 中与 N 期（=0.045）和甲胎蛋白（AFP）>20ng/ml（<0.01）相关。然而，EZH2 与年龄呈负相关（=0.027）。EZH2 高表达的 HCC 患者总生存结果明显较差。此外，EZH2 高表达患者的复发率也明显高于低表达患者（χ2=16.10，<0.001）。EZH2 相关基因中，EZH2 表达与 STAT3 表达呈负相关（R=-0.163，=0.002）。与阴性 siRNA 处理的对照组相比，EZH2 表达水平下调至 50%或更低。MTT 测定表明，EZH2-siRNA 显著影响 HCC 细胞系的活力。总之，EZH2 的过表达是 HCC 预后不良的独立生物标志物。然而，需要更多的体内研究来确定 HCC 中的下游靶基因，以提高我们对 EZH2 在 HCC 中的生物学作用的理解。
